ADMA - ADMA Biologics rallies on Q4 prelims 2021 strategic outlook

In its prelim Q4 prelim update, ADMA Biologics ([[ADMA]] +9.2%) reported $13.9M (+16% Y/Y) in total revenues (highest revenue quarter since inception); FY20 total revenues seen at $42.2M (+44% Y/Y)."2021 is poised to be a transformative year for ADMA as we continue to execute on our mission of providing specialty immune globulin products to patients and building a highly profitable, end-to-end biologics manufacturing company," president & CEO Adam Grossman commented.The company expects Q/Q and Y/Y revenue growth across 2021 and achieving profitability with peak revenues of $250M or greater by 2024.It plans to complete certain supply chain enhancements and capacity expansion programs as early as mid-2021; post FDA approval, its newly installed fill-finish machine as well as the IVIG manufacturing scale increase should enable ADMA to realize significant operating efficiencies and improved gross margins beginning potentially as early as mid-2021.By 2024, ADMA's plasma collection center network will achieve the goal

For further details see:

ADMA Biologics rallies on Q4 prelims, 2021 strategic outlook